Reflux esophagitis
Conditions
Interventions
Suspension of therapy with vonoprazan
Suspension of therapy with esomeprazole
Sponsors
Marru-clinic Yokosuka Department of Gastroenterology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who have freely provided written informed consent for the participation of this study after the oral and written sufficient explanation 2. Patients diagnosed as having reflux esophagitis by physician, and receiving the therapy with vonoprazan or esomeprazole for 4 weeks or longer 3. Patients who check 0 day a week in GerdQ Q1 and Q2
Exclusion criteria
Exclusion criteria: 1. Patients with warning signs such as vomiting, gastrointestinal bleeding (including findings of hematemesis, melena, and anemia), and sudden weight loss 2. Patients confirmed or suspected malignant lesion 3. Patients with a history of gastrointestinal resection or vagotomy 4. Patients in Irritable Bowel Syndrome 5. Patients whose participation in this study would be contraindicated due to complications such as serious hepatic disease, renal disease, or cardiac disease 6. Women who are pregnant or who may possibly be pregnant, and lactating mothers 7. Other patients whom the investigator considers unsuitable for admission to the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gerd Q total score of heartburn and acid regurgitation | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Gerd Q each score of heartburn and acid regurgitation Degrees of heartburn and acid regurgitation 2. Gerd Q each score of epigastralgia, nausea and vomiting Degrees of epigastralgia, nausea and vomiting 3. Evaluation of treatment response with Gerd Q | — |
Countries
Japan
Contacts
Public ContactYasuhiro Mizuno
Marru-clinic Yokosuka Department of Gastroenterology
Outcome results
None listed